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ABSTRACT
Vaccination is an effective strategy toprevent infectiousor
immune related diseases, which has made remarkable
contribution in human history. Recently increasing atten-
tions have been paid to mucosal vaccination due to its
multiple advantages over conventional ways. Subunit or
peptide antigens are more reasonable immunogens for
mucosal vaccination than live or attenuated pathogens,
however adjuvants are required to augment the immune
responses.Manymucosal adjuvantshavebeendeveloped
to prime desirable immune responses to different etiolo-
gies. Compared with pathogen derived adjuvants, innate
endogenous molecules incorporated into mucosal vac-
cines demonstrate prominent adjuvanticity and safety.
Nowadays, cytokines are broadly used as mucosal adju-
vants for participation of signal transduction of immune
responses, activation of innate immunity and polarization
of adaptive immunity. Desired immune responses are
promptly and efﬁcaciously primed on basis of speciﬁc
interactions between cytokines and corresponding
receptors. In addition, some other innate molecules are
also identiﬁed as potent mucosal adjuvants. This review
focuseson innateendogenousmucosaladjuvants,hoping
to shed light on the development of mucosal vaccines.
KEYWORDS mucosal vaccine, adjuvant, innate
endogenous molecules
INTRODUCTION
Mucosal vaccination is the direct strategy against infections
at the entry portal, where pathogens initiate infections via
host mucosae. Compared with other vaccinated methods,
mucosal vaccination is desirable for many reasons. Firstly
the needle free application provides safety for the vaccinator,
vaccinee and community, especially in developing countries
(Giudice and Campbell, 2006). Cold chain free delivery
reduces the cost on transportation and storage of vaccines.
Easy manipulations of mucosal immunizations help to get rid
of the dependence on vaccinators, which is ﬂexible for
vaccine administration. Moreover, mucosal immunizations
increase the compliance with recommended vaccination
schedules and reduce the side effects on vaccinee, espe-
cially children (Giudice and Campbell, 2006). The most dis-
tinct advantage of mucosal vaccination is that the speedy
delivery to mucosal sites efﬁciently elicits mucosal immune
responses, especially the secretion of mucosal IgA (Mcghee
et al., 1992). Mucosal IgA is prominent to opsonise or neu-
tralize mucosal pathogens and activate complement path-
way at the portal of entry (Walker, 2004). In addition,
mucosal vaccination also induces systemic immune
responses, including serum IgG production and cell medi-
ated responses on distal sites (Kaul and Ogra, 1998).
Mucosal surfaces are rich of immunologic organs, thus all
mucosal sites are theoretically able to be used as vaccinated
routes. On the basis of logical and practical considerations,
oral and nasal routes are focused on the delivery of mucosal
vaccines (Levine, 2003). Although oral administration of
vaccines has been successfully used against polio, cholera
and typhoid fever, intranasal delivery is the most effective
way to induce potent and broad mucosal immune responses
at multiple mucosal sites (Holmgren and Czerkinsky, 2005).
Moreover, oral delivery of large amount of immunogens
easily elicits oral tolerance and is challenged by stomach
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acids upon ingestion, inhibiting the usage of oral vaccines
(Holmgren et al., 2003; Levine, 2003). The small surface
area of nasal mucosa requires a low amount of antigens and
the absence of acidity in nasal environment keeps the sta-
bility of antigens (De Magistnis, 2006).
Live or attenuated vaccines are efﬁcient to control infec-
tious diseases. However the safety concerns put live or
attenuated vaccines to a debatable dilemma, which hinders
the process of clinical applications. It is possible that vacci-
nated organisms may revert to wild-type or even hyperviru-
lent organisms with its replication in the host. Therefore
puriﬁed protective antigens were paid more attention to new
generation mucosal vaccines. Direct mucosal administra-
tions of soluble antigens only elicit relative low immunoge-
nicity, thus safe and efﬁcacious mucosal adjuvants are often
co-administered with antigens to increase immunogenicity of
non-living vaccines (De Magistnis, 2006). Furthermore, the
adjuvant has been deﬁned as immunopotentiator distinct
from the delivery system previously (O’Hagan and Rappuoli,
2004).
Pathogen-derived adjuvants or derivatives have been
widely used on the adjuvant system of mucosal vaccines.
Although some adjuvants prime to potent and broad immune
responses, the toxic threat and side effects of non-human
products should be evaluated carefully. For example, a nasal
enterotoxin-adjuvanted inactivated inﬂuenza vaccine was
withdrawn after a short time in the market, due to the usage
of adjuvant may cause facial paresis (Mutsch et al., 2004).
Apparently the use of innate molecules as adjuvants is more
advantageous than other compounds because of less tox-
icity of innate substances (Holmgren et al., 2003). The
properties of the innate endogenous adjuvants in the
development of mucosal vaccines for protection against
infections will be extensively discussed in the following part.
CYTOKINES
Cytokines are loosely categorized as signaling proteins,
which are released by a broad range of cells. The cytokine
network activates and regulates the development of innate
and adaptive immunity, balances the humoral and cell
mediated immune responses. Thus they are critical in host
defense against infections and modulation on immune rela-
ted diseases (Dinarello, 2000). Immune responses could be
initiated by simply adding these signaling molecules either
as proteins or encoding DNAs (Holmgren et al., 2003; Cox
et al., 2006), highlighting the potential adjuvanticity on vac-
cinations. A few cytokines in immune systems have been
well studied and explored to enhance the vaccine efﬁcacy.
TYPE I IFNS
Type I interferons (IFNs) have been considered as antiviral
agents and primed the development of immune responses
(Bracci et al., 2008). Several clinical reports clearly exhibits
mucosal delivery of human IFN-α has direct prophylactic and
therapeutic effects on cancers, autoimmune diseases and
infections caused by inﬂuenza virus, RSV, measles virus,
papillomavirus, HIV and hepatitis virus (Beilharz et al., 2010).
Genes encoding chemokines, cytokines and proteases were
signiﬁcantly up-regulated with mucosal administration of type
I IFNs, which are closely associated with antigen processing
and lymphocyte activation, migration, apoptosis and protein
degradation (Tovey, 2002; Namangala et al., 2006; Tovey
et al., 2008). The treatment of IFN-α/β increased the antigen-
uptake rate of resident APCs in nasal mucus layer of mice
(Bracci et al., 2005). Mucosal administration of IFN-α in low
dose efﬁcaciously activated the proliferation of natural killer
cells, B cells and T-cell subpopulations in the peripheral
circulation (Beilharz et al., 2010). Type I IFNs play the critical
signaling role in some well researched adjuvants, including
Th1 and CTL polarized types (Proietti et al., 2002; McBride
et al., 2006). On the other hand, mucosal application of type I
IFNs as immune suppressor efﬁcaciously induces suppres-
sor Tcells, and reduces cytotoxic Tcells and related cytokine
products when encountering autoimmune and inﬂammatory
diseases (Beilharz et al., 2010). Oro-mucosal administration
of murine IFN-α signiﬁcantly reduced the production of
allergen speciﬁc IgE and the recruitment of eosinophil with-
out detectable toxicity in mice (Meritet et al., 2001).
Intranasal administration of IFN-α/β with an inﬂuenza
vaccine invoked an efﬁcient humoral response, preventing
mice from live inﬂuenza virus infection and weight loss
(Proietti et al., 2002; Bracci et al., 2005; Bracci et al., 2006).
Mice immunized with murine type I IFN and inﬂuenza virus A
vaccine presented high level of serum and mucosal anti-
bodies, associated with efﬁcacious virus clearance in the
lung (Couch et al., 2009). However human trials exhibited
that neither serum hemagglutination-inhibiting nor neutraliz-
ing antibody responses was signiﬁcantly elevated in the
presence of murine type I IFN. The mortality of mice chal-
lenged with lethal dose of inﬂuenza virus was signiﬁcantly
reduced by intranasal delivery of murine IFN-β and inacti-
vated inﬂuenza vaccine (Cao et al., 1992). Oral administra-
tion of murine type I IFN signiﬁcantly elevated the survival of
mice challenged systemically with a lethal dose of enceph-
alomyocarditis virus, vesicular stomatitis virus or varicella
zoster virus (Tovey and Maury, 1999). Intranasal immuniza-
tion with vaccinia virus co-expressing interferon-ε elevated
lung VV-speciﬁc CD8+ CD107a+ IFN-γ+ population,
enhanced lymphocyte recruitment to lung alveoli with
reduced inﬂammation and heightened functional/cytotoxic
CD8+ CD4+ T-cell subset (CD3hiCCR7hiCD62Llo) in murine
lung lymph nodes, corresponding to a rapid VV clearance in
lungs (Wijesundara et al., 2014).
The immuostimulatory effects of type I IFNs are critically
dependent upon the timing and dosage of mucosal admin-
istration (Beilharz et al., 2010). For instance, IFNs given prior
to immunogen suppressed immunoglobulin production and
class switching of B cells. Additionally, the high dose of type I
IFNs was immunosuppressive. Meanwhile type I IFNs are
regarded as immunosuppressors under the circumstances
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of autoimmune and inﬂammatory diseases. Some reports
showed the administration of type I IFNs was detrimental to
pathogen clearance (Wijesundara et al., 2014). Thus to
illustrate the enigmatic roles of type I IFNs as immunomod-
ulators or immunosuppressors requires further work on, but
not limited, delivery sites, regulating mechanism, optimal
dosages and schedules of type I IFNs, and disease indica-
tions and circumstances.
IFN-γ
IFN-γ, produced primarily by Tcells and NK cells in response
to antigens or mitogens, plays a critical role in T-cell acti-
vation and the establishment of the adaptive immunity
(Weaver et al., 2007). Intranasal delivery of murine IFN-γ
and inactivated inﬂuenza vaccine increased survival of mice
challenged with lethal dose of inﬂuenza virus (Cao et al.,
1992). Further analysis showed the titers of IgA and IgG
antibodies from IFN-γ integrated group were enhanced at
the early stage of infection, and the titer of HI antibody in the
same group was signiﬁcantly lower than that in mice given
vaccine alone at the late stage of infection. Oral adminis-
tration of murine IFN-γ signiﬁcantly elevated the survival of
mice challenged systemically with a lethal dose of enceph-
alomyocarditis virus (Tovey and Maury, 1999).
Both systemic and mucosal antigen speciﬁc IgG1 and IgA
antibodies were enhanced by intranasal co-delivery of poly-
L-lactide microencapsulated V antigen of Yersinia pestis and
IFN-γ, however this formulation was detrimental to prevent
infections by systemic bacterial challenge in the murine
model (Grifﬁn et al., 2002). A low dose of murine IFN-γ was
provided in drinking water to adult HAM/ICR mice, following
challenged with Salmonella typhimurium one day later. In
comparison with control mice, the application of IFN-γ sig-
niﬁcantly prolonged survival time and reduced the penetra-
tion of Salmonellae into intestinal epithelial cells,
development of bacteremia and mortality rate (Degre and
Bukholm, 1995). Like type I IFNs, the dosage and immune
schedule of IFN-γ should be optimized in mucosal treatment
since adverse effects were observed in some reports.
GM-CSF
Granulocyte macrophage-colony stimulating factor (GM-
CSF) enhances the recruitment and activation of APCs
(Scheerlinck, 2001). Intranasal administration of human GM-
CSF enhanced serum GM-CSF levels and increased total
leukocyte counts in rabbits (Watanabe et al., 1995). The
levels of pulmonary APCs and cytokines, including IFN-γ
and IL-12p40, were signiﬁcantly elevated in mice adminis-
trated with recombinant RSV expressing murine GM-CSF
intranasally (Bukreyev et al., 2001). Furthermore GM-CSF-
encoding virus shifted virus speciﬁc Th2 response to Th1
type. Intranasal co-administration of the HIV DNA vaccine
with mouse GM-CSF-expressing plasmid induced high lev-
els of systemic and mucosal antigen speciﬁc antibodies, and
enhanced delayed type hypersensitivity in mice (Okada
et al., 1997). Mice nasally co-immunized with adenovirus
vectors encoding murine GM-CSF and amyloid β-protein
exhibited predominant antigen speciﬁc IgG1 and IgG2b
response, suggesting a GM-CSF polarized Th2 immune
response (Kim et al., 2005). Recombinant vesicular stoma-
titis virus expressing murine GM-CSF was highly attenuated
in terms of viral dissemination and pathogenesis (Ramsburg
et al., 2005). Further analysis showed the addition of genetic
GM-CSF enhanced the recruitment of macrophage, CD8
T-cell memory and recall responses in immunized mice.
Mice orally immunized with recombinant rabies viruses
expressing GM-CSF exhibited higher number of DCs and B
cells in the periphery, higher levels of adaptive immune
responses and increased viral resistance than immunization
with the parent virus (Zhou et al., 2013). The intranasal
administration of GM-CSF expressing attenuated HSV
induced protective immune responses against lethal dose
challenge of HSV in mice (Parker et al., 2006). Pulmonary
DC numbers and secretion of immunoregulatory cytokine
IL-12 were signiﬁcantly elevated by intranasal delivery of
murine GM-CSF expressing Mycobacterium bovis BCG.
(Nambiar et al., 2010). Correspondingly, antigen-speciﬁc
CD4+ T cells increased in both mediastinal lymph nodes and
lungs. More importantly, the administration of BCG:GM-CSF
signiﬁcantly reduced the load of infected M. tuberculosis
compared with mice vaccinated with BCG alone. On the
basis of above evidence, GM-CSF facilitates uptake of co-
administrated antigens via the recruitment of APCs, thus
priming immune responses.
TNF FAMILY
Tumornecrosis factor (TNF)/TNF receptor (TNFR)superfamily
are critically involved in maintaining the homeostasis of the
immune system, including beneﬁcial and protective effects in
inﬂammation and host defense (Kayamuro et al., 2009b).
Intranasal co-administration of TNF-α along with antigen
induced effective antigen-speciﬁc systemic IgG and mucosal
IgA antibody responses in mice (Kayamuro et al., 2009a).
Mucosal application of TNF-α primed to Th2-type immune
responsesby the analysis of cytokines. Theadjuvant activity of
TNF-α was proved to be efﬁcacious and safe in mice and the
adjuvanticity of TNF-α was associated, at least in part, with
increased epithelial permeability. HIV immunogen adjuvanted
with TNF-α mutant was used as a mucosal vaccine for induc-
tion of antigen speciﬁc serum IgG and local or distal mucosal
IgA antibody responses when the combination was adminis-
trated via the nasal route of mice (Kayamuro et al., 2010a).
Other members of TNF family were also tested as mucosal
adjuvants in the murine model (Kayamuro et al., 2011). Intra-
nasal delivery of TL1A or APRIL with antigen induced strong
antigen speciﬁc mucosal and humoral immune responses.
Interestingly, the magnitude of immune responses elicited by
TNFswasequivalentwith that inducedbyCTB, indicatingsuch
candidates are promising to replace toxin-based adjuvants.
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IL-1 secreted by various types of cells is a proinﬂammatory
cytokine with a wide range of effects on the host immune
system, including up- and down-regulations of many genes
related with other cytokines, chemokines, adhesions, cell
differentiations and migrations (Thompson and Staats,
2011). Mice nasally immunized with soluble antigens com-
bined with human IL-1α or IL-1β developed humoral and cell
mediated immune responses, showing equivalent effect
induced by co-administered antigens and CT adjuvant
(Staats and Ennis, 1999). Ag-speciﬁc serum IgG, vaginal
IgG and IgA, systemic delayed-type hypersensitivity, and
lymphocyte proliferative responses were signiﬁcantly ele-
vated with co-administration of antigens and IL-1α or IL-1β.
Nasal administration of IL-1α induced potent both systemic
and mucosal innate immune responses in mice, dependent
on IL-1R1 expression of stromal cells (Thompson et al.,
2012). Moreover, the induction of adaptive immunity by IL-1α
is dependent on the CD11c+ cells. Murine IL-1α exhibited
signiﬁcant adjuvant activity on the induction of HIV-speciﬁc
serum IgG in mice with nasal route of immunization (Bradney
et al., 2002). In addition, nasal immunization of murine IL-1α
and HIV immunogen induced signiﬁcant CTL response and
Ag-speciﬁc IFN-γ-secreting cells in mice (Staats et al.,
2001). Furthermore, intranasal delivery of human IL-1α was
proved to be safe and well tolerated in primate models (Egan
et al., 2004). Tonsillar application of Streptococcus sobrinus
protein antigens and human IL-1 elicited higher levels of both
mucosal IgA and serum IgG antibodies than protein antigens
alone (Kokuryo et al., 2002). Delayed type hypersensitivity to
S. sobrinus, determined by ear swelling and increasing lev-
els of IFN-γ, was found to be induced only in rabbits
immunized with IL-1.
The intranasal administration of murine IL-1α/β with
inﬂuenza virus hemagglutinin (HA) provoked the increase of
Th1- and Th2-type cytokines, systemic IgG and mucosal IgA
(Kayamuro et al., 2010b). Moreover mice co-administrated
with IL-1α/β and HA were protected from the lethal infection
of inﬂuenza virus. Nasal administration of human IL-1β
adjuvant was as effective as subcutaneous immunization of
alum adjuvant on the level of antibodies and protection
against lethal dose challenge of Streptococcus pneumonia in
mice (Gwinn et al., 2010). Like subcutaneous ISA-51 (a
water-in-oil emulsion adjuvant) and nasal CTx adjuvants,
IL-1β was an efﬁcacious nasal vaccine adjuvant for the
induction of protective immunity against a systemic tetanus
toxin challenge. Despite of efﬁcacious adjuvanticity of IL-1,
the pleiotropic characteristic of IL-1 easily elicits undesired
immune responses, requiring well-deﬁned optimized proce-
dures to evaluate IL-1 as mucosal adjuvant.
IL-2
IL-2, mainly produced by naive Tcells encountering antigens,
contributes to the growth, proliferation and differentiation of T
cells during immune responses. By using live Lactococcus
lactis as intranasal delivery vector, bacterial expression of
murine IL-2 augmented the antigen (tetanus toxin fragment
C) speciﬁc immune responses (Steidler et al., 1998). Mean-
while recombinant bacteria were not immunogenic in mice.
HIV speciﬁc delayed type hypersensitivity response and CTL
activity were enhanced in mice administrated with genetic
murine IL-2 and antigen intranasally (Xin et al., 1998).
Moreover DNA vaccination with the IL-2 expression plasmid
induced a Th1 dominant immune response. Intranasally
delivered plasmid encoding IL-2 shifted TTor CT induced Th2
type immune response to a Th1 type response (McNeela and
Mills, 2001). The production of antigen speciﬁc IFN-γ, IL-2
and IL-4 was augmented in mice orally administrated with
plasmid expressing murine IL-2/Ig (Wierzbicki et al., 2002).
Furthermore high level of CTL activity and mucosal/serum
antibodies were elicited in the approach of genetic IL-2/Ig.
Co-administration of inactivated avian inﬂuenza virus with
IL-2 strongly enhanced the local immune response after
intranasal immunization in a chicken model (Zhang et al.,
2009). Recently, recombinant B. subtilis spores expressing a
fragment of the Helicobacter acinonychis UreB protein elic-
ited a strong cellular immune response in orally immunized
mice when co-administered with spores expressing IL-2
(Hinc et al., 2014).
Subconjunctival delivery of genetic human IL-2-gD or
peptide invoked efﬁcacious neutralizing antibodies and cel-
lular immune responses against HSV (Niethammer et al.,
2001; Inoue et al., 2002). Further virus challenge showed the
immunization of genetic IL-2-gD and peptide reduced the
clinical scores and symptoms of Herpetic Keratitis in mice. In
order to improve the efﬁcacy of vaccination in old age pop-
ulation, IL-2 was incorporated into an attenuated, cold-
adapted inﬂuenza A virus. Intranasal immunization with
human IL-2-expressing virus enhanced mucosal and cellular
immune responses in both young and aged mice in com-
parison with administration of the parent strain (Ferko et al.,
2006). More importantly, mice immunized with the IL-2-
expressing virus were completely protected against a lethal
dose challenge of homologous inﬂuenza virus. A complicate
immunized protocol was applied to the control of Simian/
Human Immunodeﬁciency Virus viremia. The nasal admin-
istration of genetic human IL-2 enhanced antigen speciﬁc
cellular immune response, which provided long lasting pro-
tection from disease progression (Bertley et al., 2004).
Inclusion of human IL-2 into the intranasally administered
liposomes containing bacterial polysaccharide from Aero-
bacter euanicum and Pseudomonas aeruginosa increased
titers of bacterial polysaccharide speciﬁc sIgA and pulmon-
ary plasma cells (Abraham and Shah, 1992). Following
analysis showed intranasal immunization with P. aeruginosa
polysaccharide and IL-2 signiﬁcantly reduced the murine
mortality from P. aeruginosa pneumonia. Mucosal immuni-
zation of mice with recombinant L. lactis NZ9000 expressing
the UreBe-IL-2 conjugated protein elicited more anti-UreB
antibodies and more cytokines such as IFN-γ, IL-4 and IL-17,
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and had a lower H. pylori burden and urease activity than
control mice (Zhang et al., 2014). To sum up, both Th1 and
Th2 immune responses are polarized by the mucosal
application of IL-2, thus efﬁcaciously preventing intracellular
and extracellular infections.
IL-4 AND IL-5
Cytokine IL-4 induces the T cell differentiation from naive
Th0 cells to Th2 cells, which subsequently produce addi-
tional IL-4 in a positive feedback loop. Furthermore, IL-4
participates into the proliferation of activated B-cell and
T-cell, and the differentiation of B cells into plasma cells.
High levels of systemic and mucosal antigen-speciﬁc anti-
bodies were induced in mice immunized genetic HIV antigen
and mouse IL-4 intranasally (Okada et al., 1997). Moreover,
the IL-4 expression plasmid mainly induced IgG1 subtype in
serum, however signiﬁcantly suppressed the delayed type
hypersensitivity and CTL response. Intranasal immunization
of poly-L-lactide microencapsulated V antigen of Y. pestis
and IL-4 induced both systemic and mucosal antigen spe-
ciﬁc IgG and IgA, however this combination vaccine reduced
the survival of mice challenged with systemic bacterial
injection (Grifﬁn et al., 2002).
IL-5 produced by Th2 and mast cells stimulates B cell
growth, increases immunoglobulin secretion and mediates
eosinophil activation. Mice intranasally inoculated with ade-
novirus expressing murine IL-5 exhibited increased viral
speciﬁc IgA titers in lung lavage ﬂuid (Braciak et al., 2000).
Correspondingly viral speciﬁc antibody-secreting cells pre-
sented high frequency in lung lymphocytes derived from
mice immunized with IL-5 expressing adenovirus. The
expression of IL-5 in a recombinant vaccinia virus vector
signiﬁcantly increased co-expressed heterologous antigen
speciﬁc IgA responses in the lungs of mice given intranasal
inocula of the virus (Ramsay and Kohonencorish, 1993).
Furthermore, the level of local IgA response to IL-5 admin-
istration peaked four-fold higher than that elicited by control
virus at 14 days after infection, and was sustained for at least
4 weeks. As Th2 primed cytokines, mucosal administrations
of IL-4 or IL-5 facilitate strong humoral immune responses.
IL-6
IL-6 is a pleiotropic cytokine that regulates both Tand B cells
(Vansnick, 1990). Tetanus toxin fragment C speciﬁc immune
responses were primed and augmented by intranasal deliv-
ered Lactococcus lactis expressing murine IL-6, including
serum IgG and mucosal IgA (Steidler et al., 1998). Intranasal
inoculation of mice with adenovirus expressing murine IL-6
increased viral speciﬁc IgA/G titers in lung lavage ﬂuid (Bra-
ciak et al., 2000). Viral speciﬁc antibody-secreting cells pre-
sented high frequency in lung lymphocytes derived frommice
immunized with IL-6 expressing adenovirus. Histological
analysis showed a large number of mononuclear cells had
accumulated under the inoculation of pIL-6.
IgG1 and IgA antibodies were provoked by intranasal
delivery of recombinant V antigen of Y. pestis coencapsu-
lated with IL-6, contributing to full protection against systemic
bacterial challenge to mice (Grifﬁn et al., 2002). Nasal
application of human IL-6 and tetanus toxin (TT) enhanced
serum TT speciﬁc antibodies and Th2 response, protecting
mice from lethal challenge with tetanus toxin (Boyaka et al.,
1999). Oral administration of human IL-6 before oral infection
with Campylobacter jejuni primed Campylobacter speciﬁc
mucosal S-IgA Ab responses (Baqar et al., 1993). IL-6-
treated animals shed 3-log-unit reduction in the number of
C. jejuni within 48 h of infection. Although cell mediated
immune responses are rarely reported in mucosal applica-
tion of IL-6, humoral immune responses are strongly
activated in the presence of IL-6.
IL-10
One role of cytokine IL-10 is to down-regulate inﬂammations.
Intranasal administration of genetic IL-10 diminished Ag-
induced delayed type hypersensitivity reactions in associ-
ated with the reduction of Ag-speciﬁc proliferation and pro-
duction of Th1 cytokines in mice (Chun et al., 1999). Daily
mucosal administration of IL-10 secreting L. lactis reduces
half symptoms of inductive or spontaneous murine colitis
(Steidler et al., 2000). Comparing with intravenous injection,
mucosal delivery required much lower dose of IL-10. Further
study proved the efﬁcacy and safety of mucosal delivery of
human IL-10 secreting L. lactis on human trials (Braat et al.,
2006). The incipient experimental allergic encephalomyelitis
was suppressed in rats nasally administrated with autoanti-
gen and human IL-10 (Xu et al., 2000). Following analysis
showed that the approach of IL-10 decreased the proliferation
of antigen-speciﬁc lymphocyte and antigen-reactive IFN-γ
secreting Th1-like cells. As an anti-inﬂammatory cytokine,
adjuvant IL-10 is promising to control autoimmune or inﬂam-
matory diseases.
IL-12
IL-12, naturally produced by DC, macrophages and human
B-lymphoblastoid cells, typically induces Th1 response and
stimulates NK, T and B cells to produce IFN-γ and TNF-α
(Trinchieri, 1995; Watford et al., 2003). Consistently, mRNA
transcripts of IFN-γ and IL-10 were elevated in mice immu-
nized with murine IL-12 via nasal route (Arulanandam and
Metzger, 1999). Intranasal co-administration of HIV genetic
antigen and mouse IL-12-expressing plasmids induced both
Th1- and Th2-type responses (Okada et al., 1997). Fur-
thermore high levels of HIV-speciﬁc CTLs and delayed type
hypersensitivity were enhanced in mice immunized with
IL-12 and HIV antigen. Ovalbumin speciﬁc antibody levels of
serum IgG2a, IgG2b and IgG3 were signiﬁcantly increased
by IL-12 given intranasally, while serum IgG1 was sup-
pressed. Incorporation of murine IL-12 to mice nasally
immunized with the combined vaccine of TT and CT
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increased the secretion of TT-speciﬁc CD4+ T cells IFN-γ
and reduced levels of Th2-type cytokines (i.e., IL-4, IL-5, IL-6
and IL-10), implying the shift of CT-induced immune
response toward Th1 type (Marinaro et al., 1999). However,
IL-12 enhanced the Th2 type responses in mice given the
combined vaccine orally. Murine IL-12 enhanced the pro-
duction of gD (bovine herpesvirus type 1) speciﬁc IgA
secreting cells, mucosal IgA/G and serum IgG in intranasally
vaccinated mice (Baca-Estrada et al., 1999).
Humoral and cellular responses were enhanced in mice
intranasally administrated with plasmid DNA encoding mur-
ine IL-12 along with glycoprotein B (gB) DNA (Lee et al.,
2003). Recipients of the co-immunization procedure showed
greater resistance to vaginal challenge with a lethal dose of
HSV-1. In another study, nasal delivery of murine IL-12 and
inﬂuenza immunogens enhanced productions of both sys-
temic and mucosal antibodies (Arulanandam et al., 1999).
Mice immunized with antigen and IL-12 displayed decreased
weight loss and signiﬁcant enhanced survival after lethal
dose challenge of inﬂuenza virus. The intranasal adminis-
tration of murine IL-12 expressing attenuated HSV induced
protective immune responses against lethal dose challenge
of HSV to mice (Parker et al., 2006).
Mice intranasally administrated with murine IL-12 secret-
ing and E7 antigen expressing L. lactis were protected from
the development of cervical cancer (Bermudez-Humaran
et al., 2005). Humoral and mixed Th1/2 immune responses
were enhanced in mice immunized with human IL-12 and
tetanus toxin intranasally, providing full protection against
lethal challenge with tetanus toxin (Boyaka et al., 1999).
IL-12 as intranasal adjuvant efﬁciently prevented pneumo-
coccal infection in murine models (Arulanandam et al., 2001;
Lynch et al., 2003; Sun et al., 2007). Mucosal and systemic
IgG2a and IgA were enhanced with the inclusion of IL-12,
corresponding to the reduction of bacterial load. Intranasal
administration of inactivated Francisella tularensis and
murine IL-12 signiﬁcantly increased the survival of mice
under lethal intranasal challenge dose of F. tularensis (Baron
et al., 2007). Neonatal mice vaccinated with pneumococcal
polysaccharide conjugate vaccine and IL-12 exhibited
enhanced IFN-γ dependent mucosal and systemic immune
responses to pneumococci, and vaccinated mice were efﬁ-
ciently prevented from both otitis media and invasive infec-
tion (Sabirov and Metzger, 2006). Moreover, the dose and
toxicity of IL-12 was reduced by the intranasal route com-
paring with the parental administration route (Huber et al.,
2003; Wright et al., 2011). Although IL-12 is regarded as Th1
type cytokine, mucosal application of IL-12 also induces
strong Th2 immune responses.
IL-15
IL-15, mainly secreted by mononuclear phagocytes, induces
cell proliferation of both innate and adaptive immune system
such as natural killer cells and T cells (Shanmugham et al.,
2006). Intranasal expression of murine IL-15 delivered by
genetic sequence with HIV antigen increased the HIV-1-
speciﬁc delayed type hypersensitivity response and CTL
activity, and decreased the serum IgG1/IgG2a ratio (Xin
et al., 1999a). Moreover, murine lymphoid cells from mice
administrated with genetic IL-15 and antigen yielded
increasing production of IFN-γ and reducing secretion of
IL-4. Intranasal administration of plasmid expressing murine
IL-15 and FMDV antigen enhanced mucosal and systemic
immune responses in animals (Wang et al., 2008). Mice
immunized with IL-15 displayed high level of antigen-speciﬁc
T-cell proliferation, CTL response and increased production
of IFN-γ in both CD4+ and CD8+ T cells isolated from the
spleen and mucosal sites.
Mucosal administration of human IL-15 cDNA enhanced
both humoral and cellular immune responses during memory
phase of vaccinated mice (Toka et al., 2004; Toka and
Rouse, 2005). Intravaginal challenge of HSV-1 showed the
application of IL-15 enhanced the Th1-dependent HSV-1-
speciﬁc response, corresponding to a limited lesion severity
and rapid elimination of the infecting virus from the distal
mucosal site. Although mucosal administration of IL-15 and
SIV vaccine preserved high levels of memory CD4+ T cell
numbers in rhesus macaques challenged with SIVmac251,
the viral load was not reduced in the immunized group (Sui
et al., 2011).
IL-18
IL-18 induces the activation of Th1, NK and CTL cells and
production of IFN-γ, and regulates the synthesis of inﬂam-
matory cytokines, including IL-2 and IL-12 (Toka et al.,
2004). Intranasal immunization of murine IL-18 and HIV
immunogen induced signiﬁcant CTL response and Ag-spe-
ciﬁc IFN-γ-secreting cells in mice (Staats et al., 2001).
Antibody levels and IFN-γ producing T cell responses
were enhanced in mice immunized with genetic murine IL-18
and antigen intranasally (Lee et al., 2003). The survival rate
of mice immunized with genetic IL-18 and antigenic DNA
increased against vaginal challenge with a lethal dose of
HSV-1. The intranasal administration of murine IL-18 with
HA induced the production of Th1- and Th2-type cytokines,
systemic IgG and mucosal IgA (Kayamuro et al., 2010b).
Moreover, high levels of CTL were elicited in the presence of
IL-18 and HA, protecting mice against a lethal inﬂuenza virus
infection. Further analysis showed the mucosal adjuvanticity
of IL-18 was dependent on the activity of mast cells.
Regarding the close association between activation of Th1
cells and IL-18, mucosal administration of IL-18 may be
speciﬁc for preventing intracellular infections.
FLT3L
Fms-related tyrosine kinase 3 ligand (Flt3L) stimulates the
proliferation and differentiation of various blood cell pro-
genitors, including Tcells, B cells, NK cells and DCs (Drexler
and Quentmeier, 2004). OVA speciﬁc mucosal and plasma
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immune responses were signiﬁcantly induced by intranasal
administration of OVA and plasmid encoded murine Flt3L in
comparison with OVA alone, leaning to a Th2 type (Kataoka
et al., 2004). CD4+ T cells from the spleen and CLNs were
highly proliferative and higher levels of IL-2 and IL-4 pro-
duction were signiﬁcantly accumulated in mice adjuvanted
with Flt3L. The numbers of CD11c+ DCs in the mucosal
effector sites, such as NPs, NALT and SMG, were remark-
ably enhanced due to nasal application of the expression
plasmid encoding the Flt3L gene. Nasal administration of
OVA and plasmid encoding mouse Flt3L enhanced OVA-
speciﬁc mucosal and plasma antibodies and elicited Th2
immune response (Fukuiwa et al., 2008). Plasmacytoid DCs
and CD8+ DCs were activated and expanded in the pre-
sence of plasmid encoding Flt3L. Mice nasally immunized
with OVA and adenovirus expressing murine Flt3L exhibited
high levels of OVA-speciﬁc mucosal and plasma antibodies
as well as hyper-proliferation of OVA-speciﬁc CD4+ T cell
and OVA-induced IFN-γ and IL-4 production in NALT, CLN
and spleen (Sekine et al., 2008). OVA-speciﬁc CTL response
was also enhanced in the spleen and CLN, and the number
of CD11b+CD11c+ DCs expressing high levels of costimu-
latory molecules was preferentially increased in NALT, which
migrated to mucosal effector lymphoid tissues. A single
intratracheal application of human Flt3L dose dependently
increased DC and T lymphocytes (CD4+ and CD8+) in rats,
with a maximum on day 3 (Pabst et al., 2003). The cells in
the lung interstitium and the bronchoalveolar space were
affected by the administration of Flt3L, and subsequent
intratracheal application of tetanus toxoid after the local Flt3L
stimulation enhanced levels of antigen speciﬁc IgA and IgG
in the lung.
Mice orally immunized with human Flt3L and CT were
resistant to subsequent CT challenge in the model of ligated
intestinal loops (Williamson et al., 1999). Flt3L-treated mice
exhibited signiﬁcantly elevated levels of CT-speciﬁc IgA Ab
titers in both intestinal ﬂuid and serum. The number of
dendritic cells were increased in NALT with the nasal appli-
cation of human Flt3L (Kodama et al., 2010). The co-
administration of Flt3L and P6 protein of non-typeable
Haemophilus inﬂuenzae induced P6-speciﬁc nasal wash IgA
and serum IgG, antibody-producing cells and enhanced
Haemophilus inﬂuenzae clearance from the nasopharynx in
mice. Moreover, the longevity of vaccination was prolonged
by nasal application of Flt3L and P6. Intranasal administra-
tion of pneumococcal surface protein A (PspA) and plasmid
encoding the murine Flt3L increased levels of PspA-speciﬁc
secretory IgA and IgG Ab responses that were correlated
with elevated numbers of CD8+ and CD11b+ DCs and IL-2-
and IL-4-producing CD4+ T cells in the NALT and CLNs
(Kataoka et al., 2011). Correspondingly, numbers of CFU in
the lungs, airway secretions and blood were markedly
reduced when mice were nasally challenged with Strepto-
coccus pneumoniae WU2. In conclusion, mucosal adminis-
tration of Flt3L activates the interconnection between innate
and adaptive immunity, which elicits both mucosal and sys-
temic immune responses.
CCR7 LIGANDS
C-C chemokine receptor type 7 (CCR7) and its ligands direct
the migration of mature DCs and establish a functional
microenvironment to prime naive T cells. A recent work
demonstrated that intranasal administration of plasmid
encoding murine Epstein-Barr virus-induced molecule 1
ligand chemokine (ELC) and HIV-1 gp140 signiﬁcantly
enhanced gp140-speciﬁc systemic and mucosal Ab
responses in mice (Hu et al., 2013). Further analysis showed
pELC co-delivery resulted in an increase of CCR7+ CD11c+
cells in mesenteric lymph nodes and both CCR7+ CD11c+
cells and CCR7+ CD3e+ cells in spleen.
Nasal and intragastric administration of genetic CCR7
ligands with herpes simplex virus 2 DNA plasmid stimulated
distal mucosal IgA responses, and CD4+ T helper cell
proliferation and CD8+ T cell-mediated CTL activity (Eo
et al., 2001b). The number of dendritic cells was enhanced
by co-delivery of CCR7 ligands in secondary lymphoid tis-
sue. Secondary lymphoid tissue chemokine (SLC) speciﬁ-
cally increased the production of Th1-type cytokines (IL-2
and IFN-γ) and ELC elicited the yield of both Th1-type and
Th2-type (IL-4) cytokines (Eo et al., 2001b). Further ana-
lysis showed co-delivery of CCR7 ligands with antigen
generated a high CTL population that was capable of rapid
expansion following infection with HSV (Toka et al., 2003).
The symptom was relieved and the survival rate was
increased in CCR7 ligands vaccinated mice under the
lethal dose challenge of HSV McKrae strain. In summary,
the migration of DCs induced by CCR7 ligands enhances
the antigen uptake at mucosal sites and antigen presen-
tation at lymphatic tissues, thus efﬁcaciously inducing
immune responses.
MIPS AND MCPS
Genetic application of CC chemokines macrophage inﬂam-
matory protein 1β (MIP-1β) and monocyte chemotactic pro-
tein 1 (MCP-1) primed Th2-type immune response, while the
CXC chemokine MIP-2 and the CC chemokine MIP-1α
elicited Th1-type pattern. Nasal approach of murine MIP-1α
elicited signiﬁcant increases in anti-OVA IgG1 and IgG2b Ab
titers followed by IgG2a and IgG3 in mice (Lillard et al.,
2003). Moreover, the production of IFN-γ, Th1 and CD8+
CTL responses were promoted in the presence of MIP-1α.
Intranasal administration of murine MIP-1β induced antigen
speciﬁc systemic IgG1 and IgG2b and mucosal IgA. Both
Th1 and Th2 responses were distinctively induced by MIP-1β.
Co-inoculation of murine MIP-1α expressing plasmid and HIV
DNA vaccine increased not only systemic and mucosal anti-
bodies, but also CTL activity and delayed type hypersensi-
tivity in mice (Lu et al., 1999). The low ratio between IgG1 and
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IgG2a indicated the dominated Th1 response in the presence
of MIP-1α.
The function of antigen-presenting cells and expressions
of costimulatory molecules (B7-1 and B7-2) were up-regu-
lated in the presence of murine MIP-1α, whereas Th1-type
CD4+ T-cell-mediated adaptive immunity was enhanced by
murine MIP-2 via increasing secretion of IFN-γ from acti-
vated NK cells (Eo et al., 2001a). In comparison with MIP-1β
and MCP-1, mucosal genetic co-transfer of MIP-2 or MIP-1α
with genetic antigen rendered recipients (mice) more resis-
tant to HSV intravaginal infection. Nasal application of
MIP-3α with P6 protein of nontypable Haemophilus inﬂuen-
zae (NTHi) induced an increase in the number of dendritic
cells in murine NALT and P6-speciﬁc nasal wash IgA and
serum IgG titers (Kodama et al., 2011). Accordingly, the
clearance of NTHi was enhanced in MIP-3α immunized
group.
RANTES
RANTES (regulated on activation, normal T cell expressed
and secreted) is an inﬂammatory chemokine that promotes
the accumulation and activation of several types of leuko-
cytes, including CD4+ T cells and macrophages (Baggiolini
and Dahinden, 1994). Intravaginally co-administered murine
RANTES-expressing plasmid (pRANTES) with antigen efﬁ-
caciously expressed at the vaginal tissues, and induced
more vaginal IgA and serum IgG immune responses than CT
adjuvant in mice (Oh et al., 2003). Intranasal administration
of plasmids carrying env and rev genes of HIV-1 and
encoding murine RANTES induced signiﬁcantly higher titers
of serum HIV-1-speciﬁc IgG, IgG2a and fecal IgA antibodies
than antigen DNA vaccination alone (Xin et al., 1999b). This
vaccinated combination also increased HIV-1-speciﬁc CTL
activity and delayed-type hypersensitivity in mice. Nasal co-
administration of murine RANTES and the antigen initiated
and enhanced Ag-speciﬁc humoral and cellular immune
responses in both mucosal and systemic compartments
(Lillard et al., 2001). Furthermore, nasal delivery of RANTES
induced proliferative and Th1- (IL-2 and IFN-γ) type
responses, and RANTES was proved to up-regulate CD28,
CD40L and CD30 expression on both resting and activated
T lymphocytes. The unique Tcell activation by RANTES may
facilitate vaccinations to achieve desirable T cell mediated
immune responses.
ANTIMICROBIAL MOLECULES
As chemotactic antimicrobial peptides for T cells, defensins
exert adjuvant activity on the induction of antigen-speciﬁc
immune response by nasal co-administration with antigens.
Antigen-speciﬁc IgG1 followed by IgG2b and IgG2a was
promoted by addition with human defensins, indicating the
development of both Th-1 and selected Th-2 type immune
responses. Furthermore, antigen speciﬁc CD4+ Th cell
responses and cytokines of IL-5 and IL-6 were observed in
the presence of defensins, corresponding to the Th1 and
Th2 responses (Lillard et al., 1999a). Nasally co-adminis-
tered human neutrophil peptide (HNP) defensins with pro-
tein antigens enhanced systemic immunity, however HNPs
provided inhibitory signals for mucosal B and T cells. Mice
intranasally immunized with HNPs displayed antigen spe-
ciﬁc proliferative responses of CD4+ and high production of
IFN-γ, IL-5, IL-6 and IL-10, indicating HNPs elicited both
Th1 and Th2 immune responses. In comparison with mice
immunized with only OVA, human HNP-1, HBD1 and HBD2
induced signiﬁcantly higher OVA-speciﬁc serum IgG,
including IgG1 and IgG2b subtypes (Brogden et al., 2003).
Moreover, the additive HNP-1, HNP-2 and HBD2 yielded
lower IFN-γ and HBD1 enhanced the production of IL-10 in
mice. Oral administration of cathelicidin LL-37 and conju-
gated antigen effectively evoked the antigen-speciﬁc sys-
temic and mucosal immune responses, especially virus
neutralization antibodies (Jang et al., 2013). Further ana-
lysis exhibited the number of germinal centers were signif-
icantly induced by chemotactic effect of LL-37 in both
Peyer’s patch and mesenteric lymph node. In addition,
strong Th1- and Th17-skewed immune responses were
elicited through CD11c+ CD70+ cell activation in Peyer’s
patch.
In comparison with BCG alone, delayed type hypersen-
sitivity response was enhanced in mice orally administrated
with lactoferrin and BCG (Chodaczek et al., 2006). Oral
administration of lactoferrin increased the frequency of
neutrophil precursors in the peripheral blood and decreased
the spontaneous production of IL-6 and TNF-α by unstimu-
lated blood cell cultures in human trials (Kruzel and Zimecki,
2002). Furthermore, patients subjected to thyroid surgery
were treated with lactoferrin, exhibiting increased immune
responsiveness. Beside the direct inhibition on pathogens,
above antimicrobial molecules are also efﬁcacious mucosal
adjuvants, attracting further experimental and clinical trials
on vaccine development.
OTHER INNATE MUCOSAL ADJUVANTS
The above listed innate molecules have been well deﬁned as
mucosal adjuvants, however other endogenous molecules
are reported to prime immune response with limited litera-
tures. Lymphotactin (Lptn), belonging to C chemokine family,
is predominantly produced by NK, CD8+ Tcells and γδ TCR+
intraepithelial lymphocytes. Nasal administration of murine
Lptn with protein antigens promoted both mucosal and
systemic immunity (Lillard et al., 1999b). Mice immunized
with antigen and Lptn displayed higher antigen-speciﬁc
proliferative responses and increased synthesis of IFN-γ,
IL-2, IL-4, IL-5, IL-6 and IL-10 of CD4+ T cells. This indicated
that Lptn induced mixed Th1 and Th2-type responses.
Eotaxin is a potent chemoattractant for eosinophils via the
eotaxin receptor CCR-3. Intranasal administration of eotaxin
caused chemotaxis of eosinophils with a clinically symp-
tomatic inﬂammatory response in the human nasal mucosa,
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which was accompanied with the increase of nasal NO,
contributing to oxidative stress (Hanazawa et al., 2000).
Thymic stromal lymphopoietin acted as a potent mucosal
adjuvant for HIV-1 gp140 vaccination in mice (Van Roey
et al., 2012). The use of murine TSLP as an adjuvant
skewed both the cellular and humoral immune responses
towards Th2 cells in mice.
The intranasal administration of murine IL-33 with HA
induced the production of Th1- and Th2-type cytokines,
systemic IgG and mucosal IgA (Kayamuro et al., 2010b).
Nasal approach of IL-33 and HA induced high levels of CTL,
efﬁcaciously protecting mice against a lethal inﬂuenza virus
infection. Like IL-18, some activity of IL-33 is related to mast
cells. B-cell activating factor (BAFF) secreted by stromal
cells is crucial for survival and maturation of B cells (Batten
et al., 2000; Kalled, 2006). Antigen speciﬁc systemic/muco-
sal antibodies were signiﬁcantly enhanced in mice adminis-
trated with replication-deﬁcient adenovirus vector expressing
murine BAFF and heat-killed P. aeruginosa intranasally,
reducing murine mortality under lethal dose challenge of
P. aeruginosa (Tertilt et al., 2009). Moreover the spatial and
temporal proximity with antigens were unnecessary for the
application of BAFF as the immune booster.
COMBINED INNATE ENDOGENOUS ADJUVANTS
Although many innate endogenous molecules are evalu-
ated as mucosal vaccine adjuvants, combined adjuvants
are required to induce desired immune responses. Co-
administration of the DNA vaccine with murine IL-12- and
GM-CSF-expressing plasmids induced high levels of HIV-
speciﬁc antibodies (Okada et al., 1997). Moreover, CTLs
and delayed type hypersensitivity were increased when
both chemokines were administered to mice intranasally.
Intranasal administration of adenovirus encoding murine
IL-5 and IL-6 acted additively to enhance local mucosal
IgA and IgG antibody responses (Braciak et al., 2000).
Correspondingly viral speciﬁc antibody-secreting cells
presented high frequency in lung lymphocytes derived
from mice immunized with IL-5 and IL-6 expressing
adenovirus.
Combinations of two or three cytokines including murine
IL-1α, IL-12, IL-18 and GM-CSF plus HIV immunogen efﬁ-
caciously enhanced mucosal IgA, induced CTL lytic activi-
ties, increased Ag-speciﬁc IFN-γ-secreting splenic cells and
CD8+ in the peripheral blood (Staats et al., 2001). The an-
tipeptide serum IgG and mucosal IgA titers were signiﬁcantly
induced by the combination of immunogens with multiple
murine cytokines, e.g. IL-1α, IL-12 and IL-18 or IL-1α, IL-12
and GM-CSF (Bradney et al., 2002). Combination of human
IL-1α and GM-CSF with antigen increased both mucosal and
systemic antibodies by intranasal vaccinated route in
macaques (Egan et al., 2004). The level of anti-DNP tear IgA
was signiﬁcantly enhanced in the lymphokine-treated rats
co-administrated with antigen and murine IL-5 and IL-6
(Pockley and Montgomery, 1991). Rhesus macaques
intranasally immunized with vaccinia virus Ankara carrying
SIV DNA and plasmid expressing IL-2 and IL-15 or GM-CSF,
IL-12 and TNF-α exhibited signiﬁcant SIV-speciﬁc mucosal
and systemic cell-mediated immunity (Manrique et al., 2011).
Both vaccinated formulations signiﬁcantly reduced the viral
titer after intravaginal SIVmac251 challenge, corresponding
to long survival time.
CONCLUSIONS AND PERSPECTIVES
This review brieﬂy describes the applications of innate
endogenous molecules on developing mucosal adjuvants.
The incorporation of these molecules signiﬁcantly reduces
the dose of antigens, enhances strong mucosal and sys-
temic antibodies, elicits cell mediated immune response and
eventually provides protections against pathogens or
immune related diseases. The safety would be increased by
the application of endogenous molecules instead of bacteria
derived or synthetic materials. The mucosal route of vaccine
delivery has been considered for a number of reasons
including direct targeting of sites where the effects of given
antigen or adjuvant are needed. Interestingly, some non-
curable or recurrent infectious diseases could be effectively
controlled by mucosal vaccinations as summarized in
Table 1.
Cytokines are broadly used as mucosal adjuvants on the
basis of their intrinsic characteristics, participating signal
transduction of immune responses, activation of innate
immunity and polarization of adaptive immunity. In use of the
speciﬁc interactions between cytokines and corresponding
receptors, desired immune responses are promptly and efﬁ-
caciously primed. The relatively short half-life of recombinant
homologues of cytokines has limited their use as vaccine
adjuvants. These difﬁculties have been overcome by encap-
sulation into liposomes, virosomes and microparticles, and
the use of cytokine expressing vectors co-administered with
DNA vaccines. Moreover, the approach of DNA vaccines
reduces the cost and increases the duration time of vacci-
nations. Beside cytokines, some other innate molecules are
also identiﬁed as potent mucosal adjuvants recently.
Although some encouraging results on mucosal adju-
vants have been achieved with different cytokines, important
adverse effects are often associated with the large and
repeated cytokine doses. Additionally, most cytokines are
pleiotropic on the immune responses, sometimes eliciting
unnecessary immune responses. The principle will be
essential for rationally selecting vaccine adjuvants and
application doses that induce potent immune responses in
the absence of undesired effects. The homologies between
human and non-human endogenous molecules vary differ-
ently, which affects the adjuvanticity in cross testing sys-
tems. Most innate mucosal adjuvants are evaluated on
animal models, requiring further human trials for safety and
efﬁcacy of these potent molecules.
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Table 1. Summary of innate endogenous adjuvants on mucosal immunization against HIV, HSV and inﬂuenza virus infections
Etiologies Antigens Adjuvants Outcomes References
HIV Plasmid encoding env





Okada et al. 1997
gp120 TNF-α Increase levels of antibodies Kayamuro et al. 2010a
C4-V3IIIB and C4-V3MN IL-1α Increase antibodies and
cellular immune responses
Staats et al. 2001
Plasmid encoding HIV-
1IIIB env and rev
Plasmid encoding IL-2 Enhance Th1 dominant
immune response
Xin et al. 1998
Plasmid encoding env
gp160 and rev genes
Plasmid encoding IL-4
or IL-12
Enhance Th1- and Th2-type
responses and production of
antibodies
Okada et al. 1997
Plasmid encoding HIV-
1IIIB env and rev
Plasmid encoding IL-15 Increase the delayed type
hypersensitivity response
and CTL activity
Xin et al. 1999a
C4-V3IIIB and C4-V3MN IL-18 Induce CTL response and Ag-
speciﬁc IFN-γ-secreting cells
Staats et al. 2001
Plasmid encoding
gp140
Plasmid encoding ELC Elicit systemic and mucosal Ab
responses
Hu et al. 2013
Plasmid encoding
gp160 and rev
Plasmid encoding MIP-1α Increase antibodies, CTL
activity and delayed type
hypersensitivity
Lu et al. 1999
Plasmids expressing






Xin et al. 1999b
gp140 Thymic stromal
lymphopoietin
Facilitate cellular and humoral
immune responses
Van Roey et al. 2012
Plasmid encoding env






Okada et al. 1997
C4-V3IIIB and C4-V3MN IL-1α, IL-12, IL-18
and GM-CSF
Enhance CTL response and
Ag-speciﬁc IFN-γ-secreting
cells
Staats et al. 2001
HSV Attenuated HSV Attenuated HSV
expressing GM-CSF
or IL-12
Protection against lethal dose
viral challenge
Parker et al. 2006
gD IL-2 Enhance humoral and cellular
immune responses, reduce
the clinical scores and
symptoms of Herpetic
Keratitis
Niethammer et al. 2001;
Inoue et al. 2002
Plasmid encoding gB Plasmid encoding IL-12 Induce humoral and cellular
immune responses,
protection against lethal dose
challenge
Lee et al. 2003
Plasmid encoding gB Plasmid encoding IL-15 Enhance the Th1-dependent
response and rapid
elimination of virus
Toka et al. 2004; Toka and
Rouse 2005
gB Plasmid encoding IL-18 Increase antibody levels, IFN-γ
producing T cell responses
and survival rate
Lee et al. 2003
gB CCR7 ligands Increase CTL population and
survival rate
Toka et al. 2003
Plasmid encoding gB Plasmid encoding MIP-2
or MIP-1α
Enhance cellular immune
responses and protect from
HSV challenge
Eo et al. 2001a
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CCR7, CC chemokine receptor type 7; ELC, Epstein-Barr virus-
induced molecule 1 ligand chemokine; Flt3L, Fms-related tyrosine
kinase 3 ligand; gB, glycoprotein B; GM-CSF, granulocyte macro-
phage-colony stimulating factor; HA, hemagglutinin; HNP, human
neutrophil peptide; IFNs, interferons; MCP-1, monocyte chemotactic
protein 1; MIP-1β, macrophage inﬂammatory protein 1β; PspA,
pneumococcal surface protein A; SLC, secondary lymphoid tissue
chemokine; TNF, tumor necrosis factor; TT, tetanus toxin.
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